Aptivus
(Tipranavir)ApprovedSmall molecule
Boehringer IngelheimTipranavir is a protease inhibitor used to treat HIV infection. It works by reducing the amount of HIV virus in the blood, which can help prevent the development of AIDS and related illnesses, though it does not cure HIV.[2] Aptivus is currently approved and in use across 6 indications[4].[1]
Aptivus is one of 206 small molecule programs targeting HIV infection. It is currently in Approved.
6
Indications
46
Total Trials
0
Active Trials
205
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
326 competitors in HIV Infection
#DrugCompanyPhaseTrials
1Aptivus
Boehringer IngelheimApproved
Leukine
SanofiPhase 3
Intron a
Merck & Co.Phase 3
Sunlenca
GileadPhase 3
Hivid
CConrado Roberto Hoffmann Filho
Phase 3
Praluent
RegeneronPhase 3
Betaseron
BayerPhase 3
PEG-Intron
Merck & Co.Phase 3
Isentress
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Proleukin
IIovance Biotherapeutics, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Adult4 trials
Interaction4 trials
Treatment4 trials
Optimizing Treatment for Treatment-Experienced, HIV-Infected People
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00537394·517 enrolled
HIV3 trials
19 more indications
HIV-1 infection3 trials
Female2 trials
HIV-12 trials
Randomized2 trials
Concentration2 trials
HBV1 trial
Toxicity1 trial
Oral1 trial
Tenofovir Disoproxil Fumarate1 trial
Atorvastatin1 trial
Platelet Function1 trial
Efficacy1 trial
Methadone1 trial
Trial1 trial
Resistance1 trial
Hepatitis B1 trial
Moderate Hepatic Insufficiency1 trial
Unspecified3 trials
Regulatory
FDA Approval Timeline[5]
Jun 22, 2005
APTIVUS
NDA NDA021814
Jun 23, 2008
APTIVUS
NDA NDA022292
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Aptivus drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Tipranavir. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Human Immunodeficiency Virus Type 1 Protease Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company